Copyright
©The Author(s) 2021.
World J Clin Cases. Sep 26, 2021; 9(27): 8061-8070
Published online Sep 26, 2021. doi: 10.12998/wjcc.v9.i27.8061
Published online Sep 26, 2021. doi: 10.12998/wjcc.v9.i27.8061
Table 1 Comparison of the baseline data between the two groups
| Group | n | Age (yr) | BMI (kg/m2) | KPS score (scores) | FIGO stage (%) | Differentiation (%) | ||||
| Stage IIB | Stage III | Stage IVA | Well differentiated | Moderately differentiated | Poorly differentiated | |||||
| Test group | 60 | 57.6 ± 6.0 | 23.2 ± 2.4 | 78.4 ± 3.0 | 13 (21.67) | 26 (43.33) | 21 (35.00) | 18 (30.00) | 27 (45.00) | 15 (25.00) |
| Control group | 60 | 55.9 ± 6.8 | 22.8 ± 2.7 | 77.8 ± 2.8 | 17 (28.33) | 21 (35.00) | 22(36.67) | 23 (38.33) | 20 (33.33) | 17 (28.33) |
| t/χ2 | 1.452 | 0.858 | 1.133 | 1.825 | 1.565 | |||||
| P value | 0.149 | 0.393 | 0.260 | 0.401 | 0.457 | |||||
- Citation: Zhao FJ, Su Q, Zhang W, Yang WC, Zhao L, Gao LY. Endu combined with concurrent chemotherapy and radiotherapy for stage IIB-IVA cervical squamous cell carcinoma patients. World J Clin Cases 2021; 9(27): 8061-8070
- URL: https://www.wjgnet.com/2307-8960/full/v9/i27/8061.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v9.i27.8061